As of May 27
| +0.35 / +1.33%|
The 11 analysts offering 12-month price forecasts for Genomic Health Inc have a median target of 31.00, with a high estimate of 39.50 and a low estimate of 25.00. The median estimate represents a +16.54% increase from the last price of 26.60.
The current consensus among 14 polled investment analysts is to Buy stock in Genomic Health Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.